Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

ClinicalTrials.gov ID: NCT02313909

Public ClinicalTrials.gov record NCT02313909. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg

Study identification

NCT ID
NCT02313909
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bayer
Industry
Enrollment
7,213 participants

Conditions and interventions

Conditions

Interventions

  • Rivaroxaban (Xarelto, BAY59-7939) Drug
  • Acetylsalicylic acid (Aspirin, BAY1019036) Drug
  • Rivaroxaban-Placebo Other
  • Aspirin-Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 22, 2014
Primary completion
Feb 14, 2018
Completion
Feb 14, 2018
Last update posted
Jan 8, 2019

2014 – 2018

United States locations

U.S. sites
38
U.S. states
21
U.S. cities
35
Facility City State ZIP Site status
Not listed Tucson Arizona 85724
Not listed Long Beach California 90806
Not listed Stanford California 94305-5119
Not listed Torrance California 90502
Not listed New Haven Connecticut 06520-8064
Not listed Gainesville Florida 32611
Not listed Joliet Illinois 60435
Not listed Iowa City Iowa 52242-1089
Not listed Lexington Kentucky 40536
Not listed New Orleans Louisiana 70121
Not listed Baltimore Maryland 21210
Not listed Boston Massachusetts 02111
Not listed Boston Massachusetts 02118
Not listed Worcester Massachusetts 01655
Not listed Ann Arbor Michigan 48109-0330
Not listed Mount Clemens Michigan 48043
Not listed New Brunswick New Jersey 08901
Not listed Buffalo New York 14203
Not listed New York New York 10016-4576
Not listed Cincinnati Ohio 45219
Not listed Cleveland Ohio 44106-2602
Not listed Cleveland Ohio 44195
Not listed Portland Oregon 97225
Not listed Portland Oregon 97239-3011
Not listed Erie Pennsylvania 16550
Not listed Philadelphia Pennsylvania 19104
Not listed Pittsburgh Pennsylvania 15212
Not listed Charleston South Carolina 29425
Not listed Columbia South Carolina 29203-8004
Not listed Nashville Tennessee 37232-5400
Not listed Austin Texas 78701
Not listed Dallas Texas 75390
Not listed El Paso Texas 79905-2709
Not listed Houston Texas 77030
Not listed San Antonio Texas 78229
Not listed Temple Texas 76504
Not listed Salt Lake City Utah 84312
Not listed Seattle Washington 98102

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 416 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02313909, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2019 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02313909 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →